Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
81 Leser
Artikel bewerten:
(0)

NCC Announces its Childhood Cancer Research Coalition Program Grant Recipients

RALEIGH, N.C., Dec. 26, 2011 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) is pleased to announce research grant recipients, which include: Peter C. Adamson, M.D., of Children's Hospital of Philadelphia; Debra L. Friedman, M.D., M.S. of Vanderbilt-Ingram Cancer Center; Thomas W. McLean, M.D. of Wake Forest University School of Medicine; Tobey J. MacDonald, M.D. of Emory University Cancer Center; Edward V. Prochownik, M.D., Ph.D. of Children's Hospital of Pittsburgh; and Alejandro Sweet-Cordero, M.D. of Stanford University Cancer Center.

Through its Childhood Cancer Research Coalition (CCRC) program, the NCC has provided support to help medical centers to better treat their pediatric cancer patients via research funding or access to chemotherapies. NCC's President Robert Landry stated, "NCC is proud to make these awards and our CCRC program will closely monitor these investigator's impact, as the research translates into advancements in pediatric cancer treatments."

Dr. Edward Prochownik, Pittsburgh Cancer Institute Professor of Pediatrics and Professor of Microbiology & Molecular Genetics commented, "We greatly appreciate your work on our behalf, especially during these times of shrinking federal funds. It has increased significantly our ability to maintain cell lines that are essential for our research." Dr. Tobey MacDonald, Director of Pediatric Neuro-Oncology at the Emory University Cancer Center in Atlanta stated, "Funding such as this by NCC is critical to helping to cultivate innovate ideas and novel concepts. We are very grateful for such support."

The cancer research programs supported by the CCRC grants include:

  • Dr. Peter Adamson - pediatric pharmacokinetic studies to determine optimal dosing of anticancer agents.
  • Dr. Debra Friedman - long-term academic and social development studies for cancer survivors.
  • Dr. Thomas McLean - usefulness of routine imaging for detecting CNS tumor recurrence in children.
  • Dr. Tobey MacDonald - investigation study of radiation's effect on the brain.
  • Dr. Edward Prochownik - delivery of drug-like molecules to disrupt the functionality of c-Myc to achieve optimal anti-tumor effect.
  • Dr. Alejandro Sweet-Cordero - optimal treatment of pediatric bone sarcomas.

The National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports relief, education, training, and research programs throughout the world. The Coalition's medical relief program has provided over $900 million worth of requested specialty pharmaceuticals, essential medicines, and medical technologies to provide access to healthcare facilities that treat underserved patients in 50 countries, including the US. For additional information, please contact NCC at: 919-821-2182 or visit us at: www.nationalcancercoalition.org

SOURCE National Cancer Coalition

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.